NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Diabetes Device Market Outlook to 2016
http://www.reportlinker.com/p0511988/The-Diabetes-Device-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
The diabetes devices market was worth $13.9bn in 2010 and with continued innovation and the increasing prevalence of this disease is poised for continued strong growth through to 2016.
This report gives coverage of the diabetes device market which incorporates both diagnostic and insulin delivery devices. Epidemiology of this disease is forecast to 2030 and the various market segments of the market are forecast through to 2016. The report includes detailed company profiles of the established key emerging companies. The regulatory environment and other key events are assessed.
Scope of this research
Identify the market potential of the diabetes device market and the various diabetes device segments.
Gain a quick and comprehensive understanding of the innovations shaping the diabetes device market.
Identify the key innovations being developed by both emerging and established players and assess their potential.
Benchmark performance in terms of revenue growth and product launch capabilities against the leading diabetes device companies.
Learn from the strategies of leading diabetes device companies to target future growth areas, avoid their mistakes, and replicate their successes
Research and analysis highlights
The global diabetes device market is projected to reach $19.6bn by 2016, growing at a CAGR of 5.9%. Continuous glucose monitoring systems will emerge as the fastest growing market segment over this period as innovative systems with improved accuracy are introduced.
The market for insulin pen devices is projected to grow at a CAGR of 13% to 2016 driven by the rapid uptake of pre-filled insulin pens and increased penetration of insulin pens in the US, where these devices are underutilized as compared to Europe.
The market is very concentrated among the leading players. The top three companies controlled more than 50% of the market. Of the top five companies, all except for Bayer have utilized acquisitions to get access to innovative technologies. The emergence of several innovative, specialist companies has challenged the dominance of the leading players.
Key reasons to purchase this research
Which will be the largest growth opportunities in the diabetes device market?
Which companies are leading the various segments of the diabetes devices market?
What are the new advances in diabetes devices and which of them offer the most significant potential in the future?
How have the leading companies established their market leading positions in the various segments of the diabetes devices market?
How have the leading companies in the diabetes device market performed financially over the last three years?
TABLE OF CONTENTS
About Business Insights 2
Disclaimer 2
Executive Summary 10
Overview of the diabetes devices market 10
Segmentation of the diabetes device market 11
Innovations in the diabetes device market 11
Key players in the diabetes device market 12
Developments in the diabetes device market 13
Chapter 1 Overview of the diabetes devices market 15
Summary 15
Introduction 16
Type-1 diabetes 16
Type-2 diabetes 17
Pre-gestational diabetes 17
Gestational diabetes mellitus (GDM) 18
Epidemiology 18
Economic burden of diabetes 22
Market size of the global diabetes devices 25
Historical market size of global diabetes devices 25
Forecast market size of global diabetes devices 25
Drivers of the global diabetes devices market 26
Increase in the prevalence of diabetes 26
Increase in the awareness of diabetes 27
Demand for regular monitoring of glucose 27
Demand for tight regulation of insulin levels in patients 27
Increase in the usage of self administered and patient convenient devices 28
Use of new devices as a strategy for differentiation and life cycle management 28
Impending patent expiries of insulin products and the growth of the biosimilars market 28
Resistors of the global diabetes devices market 29
Low compliance of glucose monitoring and treatment 29
Development of oral insulin products 29
Lack of reimbursement for new devices 29
High failure and recall rates for insulin pumps 30
Chapter 2 Segmentation of the diabetes device market 31
Summary 31
Glucose monitoring devices 32
Regular glucose monitoring devices 32
Working principle of a glucometer 33
Historical market size of regular glucose monitoring devices 33
Forecasts for regular glucose monitoring devices 35
Key companies and products 36
Continuous glucose monitoring (CGM) devices 37
Components of a CGM device 38
Historical market size of CGM devices 40
Forecasts for CGM devices 41
Reimbursement scenario for CGM devices in the US 41
Key companies and products 42
Insulin delivery devices 43
Insulin pumps 44
Components of an insulin pump 44
Historical market size of insulin infusion pumps 45
Forecasts for insulin infusion pumps 46
Key companies and products 47
Insulin pens 50
Components of an insulin pen 51
Historical market size of insulin pens 52
Forecasts for insulin pens 54
Key companies and products 55
Insulin syringes 57
Components of an insulin syringe 57
Historical market size of insulin syringes 59
Forecasts for insulin syringes 59
Key companies and products 60
Inhaled insulin devices - case study on Exubera 60
History of development of Exubera 61
Reasons for failure 61
The cost of failure 63
Conclusion 64
Current inhaled insulin products under development 64
Chapter 3 Innovations in the diabetes device market 66
Summary 66
Introduction 67
Advances in glucose monitoring devices 67
Regular glucose monitoring 68
Sanofi-Aventis 68
Mendor 68
Non-invasive glucose monitoring 68
Eyesense 69
Freedom Meditech 70
Calisto Medical 70
Diramed Technology 71
Integrity Applications 71
Glucon 73
GlucoLight 73
Glumetrics 74
Diabetes screening 75
VeraLight 75
Neurometrix 76
Eyetel Imaging 77
Advances in insulin delivery devices 78
Insulin pumps 78
Insulet 79
Medingo (acquired by Roche) 80
Cellnovo 81
MedSolve Technologies 82
Debiotech 83
Spring Health Solutions 83
Valeritas 86
CeQur 87
Calibra Medical 87
Insulin pens 88
Novo Nordisk 88
Eli Lilly 89
Sanofi-Aventis 89
Ypsomed 90
Artificial pancreas closed loop systems 90
Medtronic 90
Animas, Dexcom, and the Juvenile Diabetes Research Foundation (JDRF) 91
Boston University and Massachusetts General Hospital 91
Institute of Metabolic Science at the University of Cambridge 91
Chapter 4 Key players in the diabetes device market 93
Summary 93
Introduction 94
Leading players 94
Roche 97
Company overview 97
Financial performance 98
Key segments and product portfolio 98
Growth strategies 98
Johnson & Johnson (J&J) 99
Company overview 99
Financial performance 100
Key segments and product portfolio 100
Growth strategies 100
Bayer 101
Company overview 101
Financial performance 101
Key segments and product portfolio 102
Growth strategies 102
Abbott 103
Company overview 103
Financial performance 103
Key segments and product portfolio 104
Growth strategies 104
Medtronic 105
Company overview 105
Financial performance 105
Key segments and product portfolio 105
Growth strategies 106
Becton Dickinson (BD) 107
Company overview 107
Financial performance 107
Key segments and product portfolio 107
Growth strategies 108
Ypsomed 108
Company overview 108
Financial performance 108
Key segments and product portfolio 109
Growth strategies 110
Insulet 111
Company overview 111
Key segments and product portfolio 111
Financial performance 111
Growth strategies 112
DexCom 112
Company overview 112
Key segments and product portfolio 113
Financial performance 113
Growth strategies 113
Emerging players and OEMs 114
Agamatrix 115
Taidoc 115
EPS Biotechnology 116
Tyson Bioresearch 116
Bionime 116
Chapter 5 Developments in the diabetes device market 118
Summary 118
Introduction 119
Regulatory and market developments impacting the market 119
US FDA looking to improve standards of accuracy for glucose meters 119
Stricter regulatory requirements for infusion pumps from the US FDA 120
Changes in PMN pathway 120
Comparative effectiveness research (CER) 121
Medical device excise tax 122
Mergers and acquisitions 122
Alliances and partnerships 124
New product approvals 127
Appendix 129
Scope 129
Methodology 129
Glossary/Abbreviations 130
References 133
Table of figures
Figure 1: Working reaction of a glucometer 33
Figure 2: Global regular glucose monitoring devices market size ($bn), 200510 34
Figure 3: Forecast global market size of regular glucose monitoring devices ($bn), 201016 35
Figure 4: Leading players' share of the regular glucose monitoring device market, 2010 36
Figure 5: Components of a CGM device 39
Figure 6: Global CGM devices market size ($bn),, 200510 40
Figure 7: Forecast global market size of CGM devices ($bn), 201016 41
Figure 8: Leading players' share of the CGM device market, 2010 42
Figure 9: Block diagram of an insulin infusion pump 45
Figure 10: Global regular insulin infusion pumps market size ($bn), 200510 46
Figure 11: Forecast global market size of insulin infusion pumps ($bn), 201016 47
Figure 12: Leading players' share of the insulin infusion pump market, 2010 48
Figure 13: Components of a typical insulin pen 51
Figure 14: Global insulin pen market size ($bn), 200510 52
Figure 15: Forecast global market size of insulin pens ($bn), 201016 54
Figure 16: Leading players' share of the insulin pens market, 2009 55
Figure 17: Components of a typical insulin syringe 58
Figure 18: Global insulin syringe market size ($bn), 200510 59
Figure 19: Forecast global market size of insulin syringes ($bn), 201016 60
Figure 20: Dreamboat Inhaler device for Afrezza 65
Figure 21: Components of the GlucoTrack device 72
Figure 22: The Sentris-100 device 74
Figure 23: Scout DS diabetes screening system 76
Figure 24: Flow chart for the EyeTel Retinal Imaging Telemetry System 77
Figure 25: Patch pumps under various stages of development 79
Figure 26: OmniPod Insulin Management System 80
Figure 27: Solo MicroPump 81
Figure 28: Cellnovo insulin pump 82
Figure 29: JewelPUMP 83
Figure 30: Components of the ADI Insulin Pump 85
Figure 31: V-Go disposable insulin delivery device 86
Figure 32: CeQur insulin infuser 87
Figure 33: Finesse insulin patch-pen 88
Figure 34: Leading diabetes device companies by product approvals, US, 20052010 127
Figure 35: Leading device approvals by category, US, 20052010 128
Table of tables
Table 1: Epidemiology of diabetes by region, 20102030 19
Table 2: Top 20 countries by diabetes burden in 2030 20
Table 3: Incidence and prevalence of Type-1 diabetes in 014 year age group, 2010 21
Table 4: Healthcare expenditure for diabetes by region, 20102030 23
Table 5: Top 20 countries by healthcare expenditure on diabetes in 2030 24
Table 6: Global segmental market size of diabetes devices ($m), 200510 25
Table 7: Forecast global segmental market size of diabetes devices, ($m), 201016 26
Table 8: Recommendations for SMBG frequency 32
Table 9: Key regular glucose monitoring devices 37
Table 10: Key marketed CGM devices 43
Table 11: Key insulin pump devices 49
Table 12: Global insulin pen market size ($bn) by segment, 200510 53
Table 13: Forecast global market size ($bn) of insulin pens by segment, 201016 55
Table 14: Demand for prefilled pens across leading brands (million units), 2009 56
Table 15: Market shares of leading companies in the global diabetes device market, 2009 95
Table 16: Global diabetes device revenues of leading companies, ($m), 20072009 96
Table 17: Presence of leading players in the various diabetes device segments 97
Table 18: Roche diabetes devices revenue performance ($m), 20052010 98
Table 19: J&J diabetes devices revenue performance ($m), 20052009 100
Table 20: Bayer diabetes devices revenue performance ($m), 20052010 102
Table 21: Abbott diabetes devices revenue performance ($m), 20052010 104
Table 22: Medtronic diabetes devices revenue performance ($m), 20052010 105
Table 23: BD diabetes devices revenue performance ($m), 20052010 107
Table 24: Ypsomed diabetes devices revenue performance ($m), 20082010 109
Table 25: Insulet diabetes devices revenue performance ($m), 20052010 112
Table 26: Dexcom diabetes devices revenue performance ($m), 20072010 113
Table 27: Key acquisitions in the diabetes devices market, 20002010 123
Table 28: Partnerships in the global diabetes device market, 20072011 125
Table 29: Partnerships in the global diabetes device market, 20072011 (continued) 126
To order this report:
Pathology Industry: The Diabetes Device Market Outlook to 2016
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
The Diabetes Device Market Outlook to 2016
http://www.reportlinker.com/p0511988/The-Diabetes-Device-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
The diabetes devices market was worth $13.9bn in 2010 and with continued innovation and the increasing prevalence of this disease is poised for continued strong growth through to 2016.
This report gives coverage of the diabetes device market which incorporates both diagnostic and insulin delivery devices. Epidemiology of this disease is forecast to 2030 and the various market segments of the market are forecast through to 2016. The report includes detailed company profiles of the established key emerging companies. The regulatory environment and other key events are assessed.
Scope of this research
Identify the market potential of the diabetes device market and the various diabetes device segments.
Gain a quick and comprehensive understanding of the innovations shaping the diabetes device market.
Identify the key innovations being developed by both emerging and established players and assess their potential.
Benchmark performance in terms of revenue growth and product launch capabilities against the leading diabetes device companies.
Learn from the strategies of leading diabetes device companies to target future growth areas, avoid their mistakes, and replicate their successes
Research and analysis highlights
The global diabetes device market is projected to reach $19.6bn by 2016, growing at a CAGR of 5.9%. Continuous glucose monitoring systems will emerge as the fastest growing market segment over this period as innovative systems with improved accuracy are introduced.
The market for insulin pen devices is projected to grow at a CAGR of 13% to 2016 driven by the rapid uptake of pre-filled insulin pens and increased penetration of insulin pens in the US, where these devices are underutilized as compared to Europe.
The market is very concentrated among the leading players. The top three companies controlled more than 50% of the market. Of the top five companies, all except for Bayer have utilized acquisitions to get access to innovative technologies. The emergence of several innovative, specialist companies has challenged the dominance of the leading players.
Key reasons to purchase this research
Which will be the largest growth opportunities in the diabetes device market?
Which companies are leading the various segments of the diabetes devices market?
What are the new advances in diabetes devices and which of them offer the most significant potential in the future?
How have the leading companies established their market leading positions in the various segments of the diabetes devices market?
How have the leading companies in the diabetes device market performed financially over the last three years?
TABLE OF CONTENTS
About Business Insights 2
Disclaimer 2
Executive Summary 10
Overview of the diabetes devices market 10
Segmentation of the diabetes device market 11
Innovations in the diabetes device market 11
Key players in the diabetes device market 12
Developments in the diabetes device market 13
Chapter 1 Overview of the diabetes devices market 15
Summary 15
Introduction 16
Type-1 diabetes 16
Type-2 diabetes 17
Pre-gestational diabetes 17
Gestational diabetes mellitus (GDM) 18
Epidemiology 18
Economic burden of diabetes 22
Market size of the global diabetes devices 25
Historical market size of global diabetes devices 25
Forecast market size of global diabetes devices 25
Drivers of the global diabetes devices market 26
Increase in the prevalence of diabetes 26
Increase in the awareness of diabetes 27
Demand for regular monitoring of glucose 27
Demand for tight regulation of insulin levels in patients 27
Increase in the usage of self administered and patient convenient devices 28
Use of new devices as a strategy for differentiation and life cycle management 28
Impending patent expiries of insulin products and the growth of the biosimilars market 28
Resistors of the global diabetes devices market 29
Low compliance of glucose monitoring and treatment 29
Development of oral insulin products 29
Lack of reimbursement for new devices 29
High failure and recall rates for insulin pumps 30
Chapter 2 Segmentation of the diabetes device market 31
Summary 31
Glucose monitoring devices 32
Regular glucose monitoring devices 32
Working principle of a glucometer 33
Historical market size of regular glucose monitoring devices 33
Forecasts for regular glucose monitoring devices 35
Key companies and products 36
Continuous glucose monitoring (CGM) devices 37
Components of a CGM device 38
Historical market size of CGM devices 40
Forecasts for CGM devices 41
Reimbursement scenario for CGM devices in the US 41
Key companies and products 42
Insulin delivery devices 43
Insulin pumps 44
Components of an insulin pump 44
Historical market size of insulin infusion pumps 45
Forecasts for insulin infusion pumps 46
Key companies and products 47
Insulin pens 50
Components of an insulin pen 51
Historical market size of insulin pens 52
Forecasts for insulin pens 54
Key companies and products 55
Insulin syringes 57
Components of an insulin syringe 57
Historical market size of insulin syringes 59
Forecasts for insulin syringes 59
Key companies and products 60
Inhaled insulin devices - case study on Exubera 60
History of development of Exubera 61
Reasons for failure 61
The cost of failure 63
Conclusion 64
Current inhaled insulin products under development 64
Chapter 3 Innovations in the diabetes device market 66
Summary 66
Introduction 67
Advances in glucose monitoring devices 67
Regular glucose monitoring 68
Sanofi-Aventis 68
Mendor 68
Non-invasive glucose monitoring 68
Eyesense 69
Freedom Meditech 70
Calisto Medical 70
Diramed Technology 71
Integrity Applications 71
Glucon 73
GlucoLight 73
Glumetrics 74
Diabetes screening 75
VeraLight 75
Neurometrix 76
Eyetel Imaging 77
Advances in insulin delivery devices 78
Insulin pumps 78
Insulet 79
Medingo (acquired by Roche) 80
Cellnovo 81
MedSolve Technologies 82
Debiotech 83
Spring Health Solutions 83
Valeritas 86
CeQur 87
Calibra Medical 87
Insulin pens 88
Novo Nordisk 88
Eli Lilly 89
Sanofi-Aventis 89
Ypsomed 90
Artificial pancreas closed loop systems 90
Medtronic 90
Animas, Dexcom, and the Juvenile Diabetes Research Foundation (JDRF) 91
Boston University and Massachusetts General Hospital 91
Institute of Metabolic Science at the University of Cambridge 91
Chapter 4 Key players in the diabetes device market 93
Summary 93
Introduction 94
Leading players 94
Roche 97
Company overview 97
Financial performance 98
Key segments and product portfolio 98
Growth strategies 98
Johnson & Johnson (J&J) 99
Company overview 99
Financial performance 100
Key segments and product portfolio 100
Growth strategies 100
Bayer 101
Company overview 101
Financial performance 101
Key segments and product portfolio 102
Growth strategies 102
Abbott 103
Company overview 103
Financial performance 103
Key segments and product portfolio 104
Growth strategies 104
Medtronic 105
Company overview 105
Financial performance 105
Key segments and product portfolio 105
Growth strategies 106
Becton Dickinson (BD) 107
Company overview 107
Financial performance 107
Key segments and product portfolio 107
Growth strategies 108
Ypsomed 108
Company overview 108
Financial performance 108
Key segments and product portfolio 109
Growth strategies 110
Insulet 111
Company overview 111
Key segments and product portfolio 111
Financial performance 111
Growth strategies 112
DexCom 112
Company overview 112
Key segments and product portfolio 113
Financial performance 113
Growth strategies 113
Emerging players and OEMs 114
Agamatrix 115
Taidoc 115
EPS Biotechnology 116
Tyson Bioresearch 116
Bionime 116
Chapter 5 Developments in the diabetes device market 118
Summary 118
Introduction 119
Regulatory and market developments impacting the market 119
US FDA looking to improve standards of accuracy for glucose meters 119
Stricter regulatory requirements for infusion pumps from the US FDA 120
Changes in PMN pathway 120
Comparative effectiveness research (CER) 121
Medical device excise tax 122
Mergers and acquisitions 122
Alliances and partnerships 124
New product approvals 127
Appendix 129
Scope 129
Methodology 129
Glossary/Abbreviations 130
References 133
Table of figures
Figure 1: Working reaction of a glucometer 33
Figure 2: Global regular glucose monitoring devices market size ($bn), 200510 34
Figure 3: Forecast global market size of regular glucose monitoring devices ($bn), 201016 35
Figure 4: Leading players' share of the regular glucose monitoring device market, 2010 36
Figure 5: Components of a CGM device 39
Figure 6: Global CGM devices market size ($bn),, 200510 40
Figure 7: Forecast global market size of CGM devices ($bn), 201016 41
Figure 8: Leading players' share of the CGM device market, 2010 42
Figure 9: Block diagram of an insulin infusion pump 45
Figure 10: Global regular insulin infusion pumps market size ($bn), 200510 46
Figure 11: Forecast global market size of insulin infusion pumps ($bn), 201016 47
Figure 12: Leading players' share of the insulin infusion pump market, 2010 48
Figure 13: Components of a typical insulin pen 51
Figure 14: Global insulin pen market size ($bn), 200510 52
Figure 15: Forecast global market size of insulin pens ($bn), 201016 54
Figure 16: Leading players' share of the insulin pens market, 2009 55
Figure 17: Components of a typical insulin syringe 58
Figure 18: Global insulin syringe market size ($bn), 200510 59
Figure 19: Forecast global market size of insulin syringes ($bn), 201016 60
Figure 20: Dreamboat Inhaler device for Afrezza 65
Figure 21: Components of the GlucoTrack device 72
Figure 22: The Sentris-100 device 74
Figure 23: Scout DS diabetes screening system 76
Figure 24: Flow chart for the EyeTel Retinal Imaging Telemetry System 77
Figure 25: Patch pumps under various stages of development 79
Figure 26: OmniPod Insulin Management System 80
Figure 27: Solo MicroPump 81
Figure 28: Cellnovo insulin pump 82
Figure 29: JewelPUMP 83
Figure 30: Components of the ADI Insulin Pump 85
Figure 31: V-Go disposable insulin delivery device 86
Figure 32: CeQur insulin infuser 87
Figure 33: Finesse insulin patch-pen 88
Figure 34: Leading diabetes device companies by product approvals, US, 20052010 127
Figure 35: Leading device approvals by category, US, 20052010 128
Table of tables
Table 1: Epidemiology of diabetes by region, 20102030 19
Table 2: Top 20 countries by diabetes burden in 2030 20
Table 3: Incidence and prevalence of Type-1 diabetes in 014 year age group, 2010 21
Table 4: Healthcare expenditure for diabetes by region, 20102030 23
Table 5: Top 20 countries by healthcare expenditure on diabetes in 2030 24
Table 6: Global segmental market size of diabetes devices ($m), 200510 25
Table 7: Forecast global segmental market size of diabetes devices, ($m), 201016 26
Table 8: Recommendations for SMBG frequency 32
Table 9: Key regular glucose monitoring devices 37
Table 10: Key marketed CGM devices 43
Table 11: Key insulin pump devices 49
Table 12: Global insulin pen market size ($bn) by segment, 200510 53
Table 13: Forecast global market size ($bn) of insulin pens by segment, 201016 55
Table 14: Demand for prefilled pens across leading brands (million units), 2009 56
Table 15: Market shares of leading companies in the global diabetes device market, 2009 95
Table 16: Global diabetes device revenues of leading companies, ($m), 20072009 96
Table 17: Presence of leading players in the various diabetes device segments 97
Table 18: Roche diabetes devices revenue performance ($m), 20052010 98
Table 19: J&J diabetes devices revenue performance ($m), 20052009 100
Table 20: Bayer diabetes devices revenue performance ($m), 20052010 102
Table 21: Abbott diabetes devices revenue performance ($m), 20052010 104
Table 22: Medtronic diabetes devices revenue performance ($m), 20052010 105
Table 23: BD diabetes devices revenue performance ($m), 20052010 107
Table 24: Ypsomed diabetes devices revenue performance ($m), 20082010 109
Table 25: Insulet diabetes devices revenue performance ($m), 20052010 112
Table 26: Dexcom diabetes devices revenue performance ($m), 20072010 113
Table 27: Key acquisitions in the diabetes devices market, 20002010 123
Table 28: Partnerships in the global diabetes device market, 20072011 125
Table 29: Partnerships in the global diabetes device market, 20072011 (continued) 126
To order this report:
Pathology Industry: The Diabetes Device Market Outlook to 2016
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
